# Abdera Therapeutics

Source: https://onco.cc/companies/abdera-therapeutics/  
OnCo record `abdera-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Abdera Therapeutics engineered antibodies that carry a radioactive isotope to cancer cells, tuning how long they circulate so more radiation reaches the tumour and less reaches healthy tissue. Its first medicine targets a protein on small cell lung cancer.

## Summary

Abdera Therapeutics, based in Vancouver and Menlo Park, California, developed antibody-based radiopharmaceuticals using its ROVEr antibody engineering platform, which tunes pharmacokinetic properties so that alpha- or beta-emitting isotopes can be matched to targets with a wide range of antigen expression. Its lead programme targets DLL3 for small cell lung cancer and other solid tumours and was advancing toward the clinic at launch; founding partners were adMare BioInnovations and AbCellera. The company emerged in April 2023 with USD 142 million in combined Series A and B financing, the Series A led by Versant Ventures and Amplitude Ventures and the USD 110 million Series B led by venBio Partners with Viking Global Investors, Qiming Venture Partners USA and RTW Investments.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Vancouver
- Type: radiopharma
- Website: https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer

## Notes

- Company website abderatx.com returned HTTP 503 or no response on every attempt, so the website field points to the fetched press release copy instead. Current status is uncertain: search headlines in 2026 refer to an auction of Abdera laboratory equipment and to biotechs that closed, but no fetched primary source confirms a wind-down, so stage is left at startup. Clinical status of the DLL3 programme (a phase 1a start was reported in trade press) not confirmed from fetched pages.

## Sources

- Official website: https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer
- Endpoints News: Abdera raises $110M Series B: https://endpoints.news/abdera-raises-110m-to-push-targeted-radiotherapies-where-they-havent-gone-before/

## Connected records

- collections: [Endpoints News](https://onco.cc/collections/src-endpoints-news/)
- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- fronts: [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Radio-antibody & radio-ADC](https://onco.cc/technologies/radioimmunotherapy/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- targets: [DLL3](https://onco.cc/targets/dll3/)
- companies: [Versant Ventures](https://onco.cc/companies/versant-ventures/)

---
JSON: https://onco.cc/api/v1/entities/abdera-therapeutics.json